



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Dirk M. Anderson
Docket No.: 2852-G
Serial No: 10/802,133
Group Art Unit: 1646
Filed: March 16, 2004
Examiner: --to be assigned--
For: KITS FOR DETECTING RANKL PROTEINS OR NUCLEIC ACIDS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 CFR §§ 1.56 and 1.97 through 1.98, applicant wishes to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. The aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which may be material to the examination of the above-identified application. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Pursuant to 37 CFR § 1.98(d), copies of references already cited by the U.S. Patent and Trademark Office or submitted in a prior application from which the present application claims priority under 35 USC § 120 are not required to be submitted with the present information. Accordingly, copies are not enclosed of patents, publications, and other information listed on the accompanying Form PTO-1449 which were previously cited by or submitted to the Office in one or more of prior applications Serial No. 09/865,363 filed May 25, 2001 (now allowed), Serial No. 09/577,780 filed May 24, 2000 (now U.S. patent No. 6,419,929), and Serial No. 08/995,659 filed December 22, 1997 (now U.S. patent No. 6,242,213). The present application is a continuation of prior application Serial No. 09/865,363 which is relied upon for an earlier filing date under 35 USC 120. The information disclosure statements submitted in the aforementioned applications relied upon for priority complied with 37 CFR § 1.98(a)-(c). Certain references listed on the attached Form PTO-1449 were published after the filing date of one or more of the prior applications.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

November 16, 2004

Date

DeDe Lindholm

Signature

There are 14 U.S. patents cited on the attached Form PTO-1449 and listed below which were not previously cited by or submitted to the Office in one or more of the applications relied upon for priority. Copies of the 14 U.S. patents are not enclosed since the Office has waived the requirement under 37 CFR § 1.98 (a)(2)(i) to submit a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003. They are:

U.S. Patents

5,670,391
5,710,013
5,767,244
5,789,550
5,961,974
6,015,938
6,150,090
6,242,213
6,271,349
6,410,516
6,419,929
6,528,482
6,537,763
6,740,522

Additionally, there are 9 foreign patent documents cited on the enclosed PTO-1449 and listed below which were not previously cited by or to the Office in a prior application, and copies are enclosed herewith. They are:

Foreign Patent Documents

EP 0873998 A2
EP 0955372 A2
WO 93/08207
WO 95/33051
WO 98/28423
WO 98/54201
WO 99/29865
WO 99/65449
WO 99/65495

Finally, there are 33 other documents cited on the enclosed PTO-1449 and listed below which were not previously cited by or to the Office in a prior application, and copies are enclosed herewith. They are:

Other Documents

Baker and Reddy
Camerini et al.
Durkop et al.
Embl-est database accession No. R93478
Galibert et al.
GenEmbl database accession No. X15271
George et al.
Gibbs and Oliff

Cont.

Guise and Mundy
Huang and Schreiber
Itoh et al.
Johnson et al.
Kodaira et al.
Kwon et al.
Lynch et al.
Mallet et al.
Nakagawa et al.
Pullen et al.
Roodman et al.
Rossi et al.
Rothe et al.
Schall et al.
Simonet et al.
Smith et al.
Stamenkovic et al.
Takahashi et al.
Tsukii et al.
White
Wong et al. (2 references)
Xing et al.
Xu et al.
Yun et al.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Thus, no fee is believed to be due for the filing of this information disclosure statement. However, should it be determined that a fee is necessary, applicant authorizes the Commissioner to charge applicant's deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Applicant requests consideration of this information and passage of the application to issue.

Respectfully submitted,



Diana K. Sheiness, Ph.D.
Registration No. 35,356
Direct Dial: 206.265.7818
November 15, 2004

Correspondence address:

22932

Law Department
Immunex Corporation
1201 Amgen Court West
Seattle, WA 98119-3105
Telephone: 206.265.7000
Facsimile: 206.233.0644

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2852-G

SERIAL NO.

10/802,133

APPLICANT

Dirk M. Anderson

FILING DATE

March 16, 2004

GROUP

1646

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,670,319	09/23/97	Goeddel et al.			
	5,710,013	01/20/98	Goeddel et al.			
	5,763,223	06/09/98	Wiley et al.			
	5,767,244	06/16/98	Goeddel et al.			
	5,789,550	08/04/98	Goeddel et al.			
	5,843,678	12/01/98	Boyle			
	5,961,974	10/05/99	Armitage et al.			
	6,015,938	01/18/00	Boyle et al.			
	6,017,729	01/25/00	Anderson et al.			
	6,150,090	11/21/00	Baltimore et al.			
	6,242,213	06/05/01	Anderson			
	6,242,586	06/05/01	Gorman et al.			
	6,271,349	08/07/01	Dougall et al.			
	6,316,408	11/13/01	Boyle			
	6,410,516	06/25/02	Baltimore et al.			
	6,419,929	07/16/02	Anderson			
	6,525,180	02/25/03	Gorman et al.			
	6,528,482	03/04/03	Anderson et al.			
	6,537,763	03/25/03	Dougall et al.			
	6,740,522	05/25/04	Anderson			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	EP 0816380 A1	07.01.98	EP			
	EP 0873998 A2	28.10.98	EP			
	EP 0911342 A1	28.04.99	EP			
	EP 0955372 A2	10.11.99	EP			
	WO 93/08207	29.04.93	PCT			
	WO 95/33051	07.12.95	PCT			
	WO 96/34095	31.10.96	PCT			
	WO 97/23614	03.07.97	PCT			
	WO 98/25958	18.06.98	PCT			
	WO 98/28423	02.07.98	PCT			
	WO 98/46644	22.10.98	PCT			
	WO 98/46751	22.10.98	PCT			
	WO 98/54201	03.12.98	PCT			
	WO 99/29865	06.17.99	PCT			
	WO 99/65449	23.12.99	PCT			
	WO 99/65495	23.12.99	PCT			
	WO 01/23549	05.04.01	PCT			
	WO 02/15846	28.02.02	PCT			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2852-G	SERIAL NO. 10/802,133
INFORMATION DISCLOSURE CITATION (<i>Supplemental sheet</i>)		APPLICANT Dirk M. Anderson		
		FILING DATE March 16, 2004	GROUP 1646	
		OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)		
Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function," <i>Nature</i> 390:175-179, 1997.				
Baker, Stacey J. and Reddy, E. Premkumar, "Transducers of life and death: TNF receptor superfamily and associated proteins," <i>Oncogene</i> , 12(1):1-9, 1996.				
Boyle v. Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.				
Camerini et al., "The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family," <i>J. Immunol.</i> 147:3165, 1991.				
Durkop et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease," <i>Cell</i> 68:421, 1992.				
Embl database entry HS421358; accession no. W74421, homo sapiens cDNA clone 346544 containing alu repetitive element, Hillier et al., June, 1996.				
Embl-est database accession no. R93478, yq16f06.rl homo sapien cDNA clone 197123 5' sequence, Hillier et al., August, 1995.				
Galibert et al., "The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily," <i>J. Biol. Chem.</i> 273(51):34120-34127, 1998.				
GenEmbl database accession no. X15271, locus.HSTRGV3F, human T-cell receptor gammaV3F, Lefranc, M. P., March, 1991.				
George et al., "Current methods in sequence comparison and analysis, selected methods and applications, eds. David H. Schlesinger, Alan R. Liss, Inc., New York, pp. 124-129, 1988.				
Gibbs, Jackson B. and Oliff, Allen, "Pharmaceutical research in molecular oncology," <i>Cell</i> , 79:193-198, 1994.				
Gray et al., "P-element-induced recombination in drosophila melanogaster: hybrid element insertion," <i>Genetics</i> 144(4):1601-1610, 1996.				
Guise, Theresa A. and Mundy, Gregory R., "Cancer and bone," <i>Endocrine Reviews</i> 19(1):18-54, 1998.				
Huang, Jing and Schreiber, Stuart L., "A yeast genetic system for selecting small molecule inhibitors of protein-protein interaction in nanodroplets," <i>Proc. Natl. Acad. Sci. USA</i> , 94:13396-13401, 1997.				
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis," <i>Cell</i> 66:233, 1991.				
Johnson et al., "Expression and structure of the human NGF receptor," <i>Cell</i> 47:545, 1986.				
Kodaira et al., "Cloning and characterization of the gene encoding mouse osteoclast differentiation factor," <i>Gene</i> 230:121-127, 1999.				
EXAMINER		DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2852-G	SERIAL NO. 10/802,133
INFORMATION DISCLOSURE CITATION (<i>Supplemental sheet</i>)		APPLICANT Dirk M. Anderson		
		FILING DATE March 16, 2004	GROUP 1646	
OTHER DOCUMENTS (cont.)				
<p>Kwon et al., "cDNA sequences of two inducible T-cell genes," <i>Proc. Natl. Acad. Sci. USA</i> 86:1963, 1989.</p> <p>Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," <i>Cell</i>, 93:165-175, 1998.</p> <p>Lynch et al., "A fluorescence polarization based Src-SH2 binding assay," <i>Analytical Biochemistry</i>, 247:77-82, 1997.</p> <p>Mallet et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes – a molecule related to nerve growth factor receptor," <i>EMBO J.</i> 9:1063, 1990.</p> <p>Marra et al., The WashU-HHMI Mouse EST project, Accession Number AA170348, 16 February 1997.</p> <p>Nakagawa et al., "RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis," <i>Biochem. and Biophys. Res. Comm.</i> 253:395-400, 1998.</p> <p>Pullen et al., "CD40 –tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization," <i>Biochemistry</i> 37(34):11836-11845, 1998.</p> <p>Roodman, G. David, "Advances in bone biology: the osteoclast," <i>Endocr Rev.</i> 17(4):308-332, 1996.</p> <p>Rossi et al., "Monitoring protein-protein interactions in intact eukaryotic cells by β-galactosidase complementation," <i>Proc. Natl. Acad. Sci. USA</i> 91:8405-8410, 1997.</p> <p>Rothe, M. et al., "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins," <i>Cell</i> 83:1243-1252, 1995.</p> <p>Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor," <i>Cell</i> 61:361, 1990.</p> <p>Simonet et al., "Osteoprotegerin: A novel secreted protein involved in the regulation of bone density," <i>Cell</i> 89:309-319, 1997.</p> <p>Smith, C. et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," <i>Sci.</i> 248:1019-1022, 1990.</p> <p>Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> 8:1403, 1989.</p> <p>Suda et al., "Modulation of osteoclast differentiation by local factors," <i>Bone</i> 17(2):87S-91S; 1995.</p> <p>Suda et al., "Modulation of osteoclast differentiation," <i>Endocr Rev.</i> 13:66-80, 1992.</p> <p>Suda et al., "Modulation of osteoclast differentiation: update 1995," in <i>Endocr Rev. Monographs</i>, 4(1):266-270; 1995.</p>				
EXAMINER		DATE CONSIDERED		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2852-G

SERIAL NO.

10/802,133

INFORMATION DISCLOSURE CITATION

(Supplemental sheet)

APPLICANT

Dirk M. Anderson

FILING DATE

March 16, 2004

GROUP

1646

OTHER DOCUMENTS (cont.)

	Takahashi N et al., "A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function," <i>Biochem Biophys Res Commun</i> 1999; 256:449-455.
	Tsukii K et al., "Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 α ,25-dihydroxyvitamin D ₃ , prostaglandin E ₂ , or parathyroid hormone in the microenvironment of bone," <i>Biochem Biophys Res Commun</i> 1998; 246:337-341.
	White, Michael A., "The yeast two-hybrid system: forward and reverse," <i>Proc. Natl. Acad. Sci. USA</i> , 93:10001-10003, 1996.
	Wiley, SR et al., "Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 1995; 3(6):673-682.
	Wong et al., "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells," <i>J. of Biological Chemistry</i> 272(40):25190-25194, 1997.
	Wong et al., "TRANCE (Tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor," <i>J. Exp. Med.</i> 186(12):2075-2080, 1997.
	Wong et al., "The TRAF family of signal transducers mediates NF- κ B activation by the TRANCE receptor," <i>J. Biol. Chem.</i> 273(43):28355-28359, 1998.
	Xing et al., "Mechanisms by which NF- κ B regulates osteoclast numbers," Abstract ASBMR Meeting, U of TX Health Science Center, 1998.
	Xu et al., "Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses," <i>Immunity</i> 5:407-415, 1996.
	Yasuda et al., "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL," <i>Proc. Natl. Acad. Sci.</i> 95:3597-3602, 1998.
	Yan et al., "OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40 ¹ ," <i>J. Immunol.</i> 161:6113-6121, 1998.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.